Maxacalcitol is the third synthetic vitamin D analog, after paricalcitol and
doxercalciferol, to be marketed for the treatment of secondary hyperparathyroidism (SHPT) associated with chronic renal failure. It is a new vitamin D3 derivative with an
oxygen atom in 22-position as main structural feature (22-oxacalcitriol, OCT). This vitamin
D receptor agonist has a strong inhibitory effect on synthesis and secretion of parathyroid
hormone in the setting of severe parathyroid hyperplasia. Maxacalcitol induced only minor
effects on calcium and phosphate metabolism unlike an agent such as 1, 25(OH)2D3 that
produced hypercalcemia and hyperphosphatemia. Maxacalcitol is.
22-Oxacalcitriol is the noncalcemic analogue of vitamine D and was found to suppress parathyroid hormone synthesis and secretion.
ChEBI: Maxacalcitol is an organic molecular entity.
Prezios (Chugai Pharmaceutical Co., Ltd., Japan);Prezios, Oxarol.
